Center · Read · November 10, 2026
Nov 9 · The FDA orders a new warning on all GLP-1 drugs, including Ozempic and Wegovy, for a rare eye condition that can cause vision loss
CNBC: CNBC gives the FDA's trial count, 6.4 vs 3.8 cases per 100,000 patient-years, and Citi's view on demand.
Grade A (97/100). Article: CNBC on the FDA's GLP-1 vision-loss warning
Lehrer score 97/100 (starts at 85; +4 named, on-record sources (2+): Novo Nordisk and Citi analysts quoted by name; +4 other side quoted or given its response: Novo Nordisk says the data "do not establish a cause-and-effect relationship"; +2 key numbers sourced: "An analysis of 126 trials involving more than 134,000 patients found 6.4 cases of NAION per 100,000 patient-years"; +2 context: background or what came before: the drugs already carry a boxed warning over "a potential risk of thyroid tumors"). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → A.
Splits: Article: CNBC on the FDA's GLP-1 vision-loss warning
Same story: CBS News, New York Post
More graded coverage
- More from CNBC: Dana White offered press secretary job by Trump; CNBC adds White's Instagram reply and the post's recent turnover. (B)
- More from CNBC: CNBC quotes the articles Massie read on the floor and notes the last Cabinet impeachment, Mayorkas in 2024. (A)
- More from CNBC: CNBC lists the agenda from the Dec. 11 deadline to the debt limit, permitting and a stock trading ban. (B)
- Also graded November 10, 2026: NewsNation: NewsNation walks through Massie's eight articles and the 67 Senate votes needed to remove Hegseth. (B)
- Also graded November 10, 2026: Newsmax: Newsmax hosts a former Navy SEAL and a retired general who say Hegseth did nothing impeachable. (D)
- Also graded November 10, 2026: CBS News: CBS posts Trump asking what Hegseth has done and saying he won wars in Venezuela and Iran. (B)
- Every CNBC grade · Scores by outlet
- All stories from November 10, 2026 · Today's stories